8:45am ET
Investing
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Companies
/Healthcare
DiaMedica Therapeutics Inc
$6.70
▼ $0.04 (−0.59%) today
Markets closed · 11:36pm ET
Today · % change
Fundamentals
Market Cap
$363.5M
EPS (TTM)
$-0.74
52-Week Range
$5 – $10
Street Target
$15.50
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Minneapolis, Minnesota, focused on developing innovative therapies for neurological and kidney diseases. Its lead product candidate, DM199, aims to enhance renal function in patients with diabetic kidney disease, addressing significant unmet medical needs in this patient population. With a promising pipeline and a strong commitment to clinical advancement, DiaMedica is well-positioned to deliver transformative treatment options that could significantly improve patient outcomes in the biopharmaceutical landscape. The company's strategic approach underscores its potential for growth and impact in the healthcare sector.
